4//SEC Filing
BERNS PAUL L 4
Accession 0001610717-25-000031
CIK 0001885522other
Filed
Feb 19, 7:00 PM ET
Accepted
Feb 20, 5:14 PM ET
Size
7.9 KB
Accession
0001610717-25-000031
Insider Transaction Report
Form 4
BERNS PAUL L
DirectorSee Remarks
Transactions
- Sale
Common Stock
2025-02-18$1.69/sh−13,871$23,468→ 7,405,004 total
Holdings
- 133,097(indirect: See footnote)
Common Stock
- 133,097(indirect: See footnote)
Common Stock
- 133,097(indirect: See footnote)
Common Stock
Footnotes (5)
- [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 19, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation.
- [F2]This transaction was executed in multiple trades in prices ranging from $1.66 to $1.745, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]Held by LULU TRUST OF 2024 FBO AB.
- [F4]Held by LULU TRUST OF 2024 FBO OB.
- [F5]Held by LULU TRUST OF 2024 FBO HB.
Documents
Issuer
Neumora Therapeutics, Inc.
CIK 0001885522
Entity typeother
Related Parties
1- filerCIK 0001202769
Filing Metadata
- Form type
- 4
- Filed
- Feb 19, 7:00 PM ET
- Accepted
- Feb 20, 5:14 PM ET
- Size
- 7.9 KB